Global CRISPR Technology Market Overview
CRISPR technology market size was valued at USD 3.6 Billion in 2022. The CRISPR Technology market industry is projected to grow from USD 4.19 Billion in 2023 to USD 14.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.50% during the forecast period (2024 - 2032).Rising demand for gene therapies and technological advancements are the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
CRISPR Technology Market Trends
- Rising advancements in CRISPR delivery systems are driving the market growth
The precise and targeted distribution of CRISPR components into cells is made possible by advancements in nanoparticle-based delivery methods. By preventing degradation of the CRISPR cargo, increasing cellular absorption, and enabling regulated release, nanoparticles can increase overall efficacy and lessen off-target consequences. CRISPR components are frequently delivered using viral vectors, such as lentiviruses and adeno-associated viruses (AAVs). Improvements are still being made to these vectors to increase their safety and effectiveness in therapeutic applications by optimizing them for increased payload capacity, tissue selectivity, and decreased immunogenicity.
Personalized medicines are made possible by the precise and targeted gene alterations made possible by CRISPR technology. The area of medicine is changing with the implementation of CRISPR in the development of personalized medicines, owing to its capacity to customize treatments based on an individual's genetic composition. CRISPR is now a mainstay in the area of gene therapy. Using technology, genetic defects causing various diseases can be corrected. The development of CRISPR-based gene therapies has given patients with genetic abnormalities new alternatives for therapy, giving them hope for previously incurable conditions.
Applications of in vivo CRISPR eliminates the need to separate and modify cells outside of the body by enabling direct targeting and editing of genes within the living organism. In addition to increasing the number of possible therapeutic interventions, this strategy streamlines the delivery procedure. Gene editing applies to a broad range of tissues and organs, including those that are difficult to access using ex vivo techniques, thanks to the capabilities of in vivo CRISPR. Treatment potential for a wide range of genetic disorders, malignancies, and other diseases is improved by this broad application.
For instance, Mammoth Biosciences raised about USD 195 million in investment in September 2021 based on the company's CRISPR technology, Cas 14. According to the National Center for Advancing Translational Sciences, the Somatic Cell Genome Editing (SCGE) Programme at the National Institutes of Health (NIH) also gave out 24 more funds to researchers in the US and Canada in 2020. Over the following four years, a total of USD 89 million in advance grants for genome editing, including CRISPR, will be given out by the SCGE Programme. With funding of almost USD 190 million distributed over six years, this raises the total number of sponsored initiatives to 45. Throughout the estimate, the CRISPR technology market is expected to grow thanks to grants from government institutes and support for industry participants. Thus driving the CRISPR Technology market revenue.
CRISPR Technology Market Segment Insights
CRISPR Technology Product & Services Insights
The CRISPR Technology market segmentation, based on product & services, includes (products [CRISPR kits & enzymes, CRISPR libraries, and other products (design tools, antibodies, other reagents)] and services [gRNA design & vector construction, cell line engineering, screening services, and other services (epigenome editing and transcriptional activation)]). The product (CRISPR kits & enzymes) segment dominated the market. Enzymes and CRISPR kits are essential for creating disease models for scientific study. Scientists can replicate diseased circumstances in cells or creatures by introducing certain genetic abnormalities linked to diseases. This method is useful for researching the causes of diseases and evaluating proposed treatments.
The services (screening services) segment is expected to be the fastest-growing segment of the CRISPR Technology market during the forecast period. Researchers can conduct functional genomics studies across the genome because of CRISPR screening services. Through methodical targeting and modification of individual genes, these services facilitate the identification of genes that are pivotal in particular biological processes, pathways, or illnesses.
CRISPR Technology Application Insights
Based on application, the CRISPR Technology market segmentation includes drug discovery & development, agriculture, and other applications (biofuels, veterinary). The drug discovery & development category has the largest market share. The systematic evaluation of the impact of gene modifications on cellular phenotypes and CRISPR screening facilitates the discovery of putative therapeutic options. In the early phases of drug development, this procedure aids in optimizing lead compounds and producing hits.
Throughout the forecast period, the CRISPR Technology market’s agriculture segment is anticipated to grow at the quickest rate. Crops resistant to pests can grow more easily, thanks to CRISPR. To minimize the environmental effects and lessen the need for chemical pesticides, genetic alterations can be introduced to plants to make them less attractive to pests or more resistant to common agricultural pests.
Figure 1: CRISPR Technology Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
CRISPR Technology End User Insights
Based on end users, the CRISPR Technology market segmentation includes pharmaceutical & biotechnology companies, academic & research institutes, and others (CROs & CDMOs). The pharmaceutical & biotechnology company’s category leads the market. Immunotherapy study uses CRISPR to alter immune cells, improving their ability to treat cancer. CRISPR-edited cells are used by biotech and pharmaceutical businesses to create innovative immunotherapeutic strategies.
During the projection period, the CRISPR Technology market’s academic & research institutes segment is anticipated to grow fastest. Researchers use CRISPR to examine bacterial and viral infections, among other infectious disorders. This entails developing gene-modified cellular and animal models to study host-pathogen interactions and pinpoint possible targets for treatment.
CRISPR Technology Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American CRISPR Technology market area will dominate this market. The pharmaceutical and biotechnology industries are well-established and cutting-edge in North America, especially in the United States. Leading biotech regions, such as the San Francisco Bay Area and the Boston-Cambridge area, are home to several businesses at the forefront of CRISPR research and development.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CRISPR TECHNOLOGY MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's CRISPR Technology market accounts for the second-largest market share due to prestigious universities and research centers in Europe actively supporting the development of CRISPR technology. These organizations conduct cutting-edge research, encouraging creativity and offering a strong platform for creating CRISPR applications. Further, the German CRISPR Technology market held the largest market share, and the UK CRISPR Technology market was the fastest-growing market in the European region.
The Asia-Pacific CRISPR Technology Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to many countries in the Asia-Pacific region having initiated extensive projects related to genetic research. These projects aim to investigate the possible uses of CRISPR technology in precision medicine and therapies and the genetic underpinnings of various disorders. Moreover, China’s CRISPR Technology market held the largest market share, and the Indian CRISPR Technology market was the fastest-growing market in the Asia-Pacific region.
CRISPR Technology Key Market Players & Competitive Insights
The CRISPR Technology market continues to grow due to major players investing heavily in R&D to expand their product offerings. Market participants also participate and take several strategic initiatives to strengthen their footprint. The industry has seen significant developments with the launch of new products, agreements, mergers and acquisitions, higher investment, and collaboration with other companies. For the CRISPR Technology industry to expand and prosper in a market that is becoming more competitive and dynamic, it must offer reasonably priced products.
Manufacturing locally to save operational costs is one of the main business tactics manufacturers adopt in the worldwide CRISPR Technology industry to support clients and expand the market sector. The CRISPR Technology industry has greatly benefited medicine in the last few years. Major players in the CRISPR Technology market, including Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), and others, are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific Inc. supplies tools for medicine, analytical equipment, consumables and reagents, software, and services for handling difficult analytical problems in clinical, research, and diagnostic labs. It provides answers for synthetic biology, flow cytometry, and cellular biology. Products from the company include technologies for molecular biology, genetic sequencing, electron microscopy, protein analysis, and mass spectrometry. The company provides services to the environmental, industrial quality, and process control sectors, pharmaceutical and biotech industries, academic and research institutions, clinical diagnostic labs, government agencies, etc. It offers its goods and services through third-party distributors, e-commerce, and a direct sales force. Thermo Fisher Scientific Inc. introduced the new Gibco CTS TrueCut Cas9 Protein, made under GMPs, in April 2022 to facilitate genome editing for manufacturing and research purposes, including the study of CAR T-cell therapy.
The biopharmaceutical firm Merck & Co Inc. is dedicated to researching, developing, producing, and distributing pharmaceuticals, vaccines, biologic therapies, and animal health products. It provides prescription medications for treating diabetes, cancer, immune system problems, infectious diseases, and cardiovascular conditions. The company sells vaccinations, poultry, cattle, and aquaculture supplies, among other items related to animal health. Merck supplies pharmaceuticals to wholesalers, retailers, hospitals, government organizations, and managed health care providers. It also supplies veterinarians, distributors, and animal producers with animal health products. In October 2020, Merck announced that it had signed licenses for its CRISPR technology with Takara Bio USA, Inc., a biotechnology company based in Mountain View, California, USA, and PanCELLa, a cell treatment company based in Toronto, Canada.
Key Companies in the CRISPR Technology market include
-
Thermo Fisher Scientific, Inc. (US)
-
Merck KGaA (Germany)
-
Agilent Technologies, Inc. (US)
-
Genscript Biotech Corporation (China)
-
CRISPR Therapeutics AG (Switzerland)
-
Editas Medicine (US)
-
Intellia Therapeutics, Inc. (US)
-
Beam Therapeutics Inc. (US)
-
Caribou Biosciences, Inc. (US)
-
Lonza Group, Ltd. (Switzerland)
-
Danaher Corporation (US)
-
PerkinElmer, Inc. (US)
-
Hera Biolabs (US)
-
OriGene Technologies, Inc. (US)
-
Cellecta, Inc. (US)
-
Mammoth Biosciences, Inc. (US)
-
Applied StemCell (US)
-
New England Biolabs Inc. (US)
-
ToolGen Inc. (South Korea)
-
GeneCopoeia, Inc. (US)
-
Others
CRISPR Technology Industry Developments
May 2023:Thermo Fisher Scientific establishes a cell therapy facility at UCSF to expedite the advancement of innovative therapeutics. From a recently opened cGMP manufacturing facility adjacent to the Mission Bay campus of UCSF Medical Centre, Thermo Fisher Scientific Inc., and the University of California, San Francisco accelerated advanced cell therapies for difficult-to-treat conditions, including cancer, rare diseases, and other illnesses.
November 2021:GenScript declared the opening of its GenWand Double-Stranded DNA (dsDNA) Service, intended to be used in T cell engineering to produce a CRISPR knock-in homology-directed repair (HDR) template.
CRISPR Technology Market Segmentation
CRISPR Technology Product & Services Outlook
CRISPR Technology Application Outlook
CRISPR Technology End User Outlook
CRISPR Technology Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
|
Report Attribute/Metric
|
Details
|
|
Market Size 2022
|
USD 3.6 Billion
|
|
Market Size 2023
|
USD 4.19 Billion
|
|
Market Size 2032
|
USD 14.23 Billion
|
|
Compound Annual Growth Rate (CAGR)
|
16.50% (2024-2032)
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024-2032
|
|
Historical Data
|
2018- 2022
|
|
Market Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Product & Services, Application, End User, and Region
|
|
Geographies Covered
|
North America, Europe, Asia Pacific, and the Rest of the World
|
|
Countries Covered
|
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
|
|
Key Companies Profiled
|
 Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), and Others
|
|
Key Market Opportunities
|
Rising therapeutic innovation and personalized medicine and expansion in agriculture and food security
|
|
Key Market Dynamics
|
Rising demand for gene therapies and technological advancements
|
Frequently Asked Questions (FAQ) :
The CRISPR Technology market size was valued at USD 3.6 Billion in 2022.
The market is projected to grow at a CAGR of 16.50% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), and Others.
The products (CRISPR kits & enzymes) category dominated the market in 2022.
Drug discovery & development had the largest share of the market.
